| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Psychotherapists at the Massachusetts General Hospital (MGH) have undergone training by lead business Fluence toward participating in Tryp Therapeutics (OTCQB:TRYPF)’ Phase 2a trial assessing psilocybin-assisted psychotherapy on adult participants with treatment-resistant Irritable Bowel Syndrome (IBS) who experience chronic abdominal pain and other debilitating gastrointestinal symptoms.
Many of these patients typically suffer from fibromyalgia, anxiety and fatigue, conditions currently targeted for treatment with psilocybin.
The primary efficacy endpoint of this trial is the improvement in abdominal pain, with additional assessments including changes in brain connectivity and responses to pain at baseline, four weeks, six months and twelve months post-sessions.
“Symptoms occurring at the mind-body interface, such as disorders of gut-brain interaction, are often inadequately addressed by conventional psychological and somatic therapies alike,” explained Harvard professor and the study’s PI Dr. Franklin King. “Given promising research suggesting that psychedelics bypass typical medical paradigms, we believe this is an extraordinarily promising avenue of research with significant potential benefit for patients."
Fluence co-founder and CVO Dr. Elizabeth Nielson, Ph.D., added that “studying psilocybin treatment for IBS, an indication that crosses the boundaries of gastroenterology and psychiatry, is a true innovation."
April 13th at the Fontainebleau Miami Beach Hotel will be THE place to set up deals, raise money, meet investors and key partners, and learn from the industry’s greatest.
Get your tickets now and don’t miss out!
Photo: Benzinga edit with photo by Pexels.
Posted In: TRYPF
